IN8bio, Inc. (NasdaqCM: INAB)
Health Care · Biotechnology · US
$1.17
-8.59% today · -41.6% 1Y
IN8bio, Inc. (NasdaqCM: INAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.62M and employs 18 people.
Over the last twelve months the share price has lost 41.6%, trading between 0.88 and 2.73.
Tweenvest scores IN8bio, Inc. across four factors: quality 26/100. Its strongest factor is quality.
INAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.62M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.48
- Dividend yield
- —
- Beta (5Y)
- 0.28
- 52-week high
- $2.73
- 52-week low
- $0.88
- Avg volume (3M)
- —
- Shares outstanding
- 9.86M
- Employees
- 18
- Next earnings
- —
About IN8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
- ISIN
- US45674E2081
- Founded
- 2016
- Listed since
- Jul 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.